Medical News Asia – Page 2 – Medical News Asia

Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan

12 September 2018/0 Comments/in Medical News Asia, Haematology, Oncology, Targeted Therapies/by scienterrific

TOKYO and MUNICH and BASKING RIDGE, N.J., September 11, 2018 — The Japan Ministry of Health, Labour and Welfare (MHLW) has granted quizartinib (AC220, Daiichi Sankyo), an investigational inhibitor of FLT3, the Orphan Drug designation for the treatment of acute myeloid leukaemia (AML) harbouring FLT3-mutations.

Capmatinib plus gefitinib promising in MET-dysregulated NSCLC

11 September 2018/0 Comments/in China, Lung Cancer, Oncology, Targeted Therapies/by scienterrific

The combination capmatinib (INC280, Novartis) plus gefitinib (Iressa®, AstraZeneca) showed promising, early phase efficacy in patients with mesenchymal-epithelial transition factor (MET)-dysregulated and epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

9 September 2018/0 Comments/in China, Medical News Asia, Oncology, Immunotherapy/by scienterrific

CARsgen Therapeutics, a Shanghai-based clinical-stage immune-oncology company committed to developing Chimeric Antigen Receptor T (CAR-T) cell therapies for cancer, presented preliminary data of their first-in-class CAR-Claudin18.2 T-cell clinical trial in pancreatic and gastric cancer patients during the 2018 CAR-TCR Summit in Boston.

DRIVER connects cancer patients in China and the United States to the best care

7 September 2018/0 Comments/in China, Medical News Asia, Oncology/by scienterrific

SAN FRANCISCO and SHANGHAI, Sept. 6, 2018/PRNewswire/ — Today, Driver, a global technology platform that connects cancer patients to the best treatments, launches in the United States and China. Driver’s platform enables any patient, anywhere in the world, to access treatment options across an unprecedented network of cancer centres without leaving home.

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

22 August 2018/0 Comments/in Breast Cancer, Medical News Asia, Genitourinary Cancer, Lung Cancer, Melanoma & Skin Cancer, Oncology, Immunotherapy, Translational Research/by scienterrific

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient’s immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

PolyU Researchers Develop Novel Self-fitting Scaffold for Bone-Regeneration

16 August 2018/0 Comments/in China, Medical News Asia/by scienterrific

HONG KONG, August 15, 2018 /PRNewswire/ — A group of researchers from the Hong Kong Polytechnic University (PolyU) in close collaboration with Sichuan University have successfully designed and manufactured a novel bone scaffold that can be safely implanted into bone defects, induce bone-regeneration, and enhance the recovery of bone injuries and fractures.

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

13 August 2018/0 Comments/in China, Medical News Asia, Lung Cancer, Oncology, Targeted Therapies/by scienterrific

HONG KONG, CHINA – 13 August 2018 – Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), announced that its innovative in-house developed oncology drug pirotinib has commenced into Phase II Clinical testing in China following the completion of a Phase I clinical trial in three renowned cancer research centres in the United States.

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

4 April 2018/1 Comment/in China, Lung Cancer, Oncology, Targeted Therapies/by Stijn van den Borne, MSc

Crizotinib in Asian NSCLC patients with ROS1 alterations was associated with a 71.7% objective response rate (ORR) with a median duration of response (DOR) of 19.7 months (95% CI, 14.1 months – not reached). Learn more about the results with crizotinib in East-Asian non-small cell lung cancer (NSCLC) patients harbouring c-ros oncogene 1 (ROS1) rearrangements.